| 2018-07-10 |
1 |
Complaint |
United States Patent Nos. 5,635,517 (the “’517
patent”), 6,315,720 (the “’720 patent”), 6,561,977 (the…
patent”), and 8,431,598 (the “’598 patent”), all owned by Celgene (collectively, “the patents-in-
…(the “’977 patent”), 6,755,784 (the “’784
patent”), 7,189,740 (the “’740 patent”), 7,465,800 (the “’800…’800 patent”), 7,855,217 (the “’217
patent”), 7,968,569 (the “’569 patent”), 8,315,886 (the “’886 patent…,717 (the “’717
patent”), 8,530,498 (the “’498 patent”), 8,626,531 (the “’531 patent”), 8,648,095 (the |
External link to document |
| 2018-07-10 |
40 |
|
Judgment, the term Patents-in-Suit shall mean U.S. Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784; … the term “Patents—in—Suit” shall mean U.S.
Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784… 4. Until expiration of the Patents.ineSuit, Lotus, including any of Its
successors…parties in connection with any infringement of the Patents-in-Suit by
any such third panics in connection…C.F.R. § 31 4.94(a)( 12) with respect to the Patents-in-Suit.
9. Nothing |
External link to document |